Study Library

 

 

Drug - Drug Interaction

 

  1. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52(5):479-486. Ref ID: 3
  1. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14(2):90-98. Ref ID: 14
  1. Tremaine L, Wilner K, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997; 32[suppl 1]:31-36. Ref ID: 111
  1. Gardner MJ, Baris BA, Wilner KD, Preskorn SH. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997; 32(1):43-49. Ref ID: 5
  1. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997; 33(4):659-665. Ref ID: 202
  1. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997; 17(4):284-291. Ref ID: 104
  1. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmcol 2001; 21(2):161-166. Ref ID: 336
  1. Reyes JF, Preskorn SH, Khan AY, Kumar D, Cullen EI, Perdomo CA et al. Concurrent administration of donepezil HCI and risperidone in patients with schizophrenia:  Assessment of pharmacokinetic changes and safety following multiple oral doses. BJCP 2004; 58(1):50-57. Ref ID: 359
  1. Preskorn SH, Greenblatt DJ, Flockhart DA, Luo Y, Perloff ES, Harmatz JS et al. Comparison of duloxetine, escitalopram and sertraline effects on cytochrome P450 (CYP) 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007; 27(1):28-34. Ref ID: 527

 

Pharmacokinetics Correlated with Pharmacodynamics

 

  1. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57(5):503-509. Ref ID: 433
  1. Harvey AT, Flockhart DA, Gorski JC, Greenblatt DJ, Burke M, Werder SF et al. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. J Clin Pharmacol 2004; 44:1173-1184. Ref ID: 387
  2. Preskorn SH, A Patroneva, et al. (2007). "A comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects". The Journal of the European College of Neuropsychopharmacology 17 (4): S339. Ref ID: 8532

 

Special Populations

 

  1. Findling RL, Preskorn SH, Marcus RN, Magnus RD, D'Amico F, Marathe P et al. Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 2000; 39(8):1008-1016. Ref ID: 294
  1. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmcol 2001; 21(2):161-166. Ref ID: 336
  1. Ong,V.S., Deng,C., Murray,M., Lowe,D., Kittrelle,J., and Preskorn,S.H. 2007. Lack of Hemodynamic Effect of MEM 1003, A Dihydropyridine Calcium-Channel Blocker:  An Exposure-Safety Relationship Assessment. Clinical Pharmacology & Therapeutics 81:S64. Ref ID:  8355

 

Efficacy Trial

 

  1. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J et al. Efficacy and safety in mirtazapine in depressed patients after SSRI treatment failure:  An open-label trial. J Clin Psychiatry 2001; 62(6):413-420. Ref ID: 343
  1. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild A, Snavely D et al. Demonstration of the efficacy and safety of a novel substance P(NK1) receptor antagonist (SPA) in major depression. Neuropsychopharmacology 2004; 29(2):385-392. Ref ID: 344
  1. Wesnes,K.A., Preskorn,S.H., Friesen,S., Edgar,C., and Mikkelson,B.O. 2002. NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer's Disease (AD). Clin Pharm Ther 71:17. Ref ID: 367

 

Study Methodology

 

  1. Khan AY, Preskorn SH, Baker B. Effect of study criteria on recruitment and generalizability of the results. J Clin  Psychopharmacol 2005 Jun;25(3):271-5. Ref ID: 442

 

PK and Formulation

 

  1. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 2006;44(11):1117- 33. Ref ID: 466

 

Food - Drug Interaction

 

  1. Cascade,E.F., Kalali,A.H., and Preskorn,S.H. 2007. EMSAM:  The First Year. Psychiatry 4:19-21. Ref ID:  8092
  1. Preskorn,S.H., Lombardo,I., Alderman,J., Wilner,K., and Miceli,J. 2007. Effect of Food on Absorption of Ziprasidone. Clinical Pharmacology & Therapeutics 81:S82. Ref ID:  8317